Boosting the arsenal against COVID-19 through computational drug repurposing.
作者信息
Ciliberto Gennaro, Cardone Luca
机构信息
Scientific Directorate, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.
Tumor Immunology and Immunotherapy Unit, Department of Research, Advanced Diagnostics, and Technological Innovations, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.
出版信息
Drug Discov Today. 2020 Jun;25(6):946-948. doi: 10.1016/j.drudis.2020.04.005. Epub 2020 Apr 15.
Abstract
摘要
相似文献
1
Boosting the arsenal against COVID-19 through computational drug repurposing.通过计算药物重新利用增强对抗新冠病毒的手段。
Drug Discov Today. 2020 Jun;25(6):946-948. doi: 10.1016/j.drudis.2020.04.005. Epub 2020 Apr 15.
2
Rapid repurposing of drugs for COVID-19.用于治疗新冠肺炎的药物快速重新利用。
Science. 2020 May 22;368(6493):829-830. doi: 10.1126/science.abb9332. Epub 2020 May 8.
3
Fight against novel coronavirus: A perspective of medicinal chemists.抗击新型冠状病毒：药物化学家的视角。
Eur J Med Chem. 2020 Sep 1;201:112559. doi: 10.1016/j.ejmech.2020.112559. Epub 2020 Jun 12.
4
Potential of Approved Antimalarial Drugs for Repurposing Against COVID-19.抗疟药物在新冠病毒治疗中的再利用潜力。
OMICS. 2020 Oct;24(10):568-580. doi: 10.1089/omi.2020.0071. Epub 2020 Jul 30.
5
Databases for the targeted COVID-19 therapeutics.针对新型冠状病毒肺炎的治疗药物数据库。
Br J Pharmacol. 2020 Nov;177(21):4999-5001. doi: 10.1111/bph.15234. Epub 2020 Sep 28.
6
Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?多发性硬化症中干扰素-β的三十年：我们能否将这些信息用于治疗新型冠状病毒2感染？
Front Immunol. 2020 Jun 18;11:1459. doi: 10.3389/fimmu.2020.01459. eCollection 2020.
7
Drug repositioning is an alternative for the treatment of coronavirus COVID-19.药物重定位是治疗冠状病毒 COVID-19 的一种替代方法。
Int J Antimicrob Agents. 2020 Jun;55(6):105969. doi: 10.1016/j.ijantimicag.2020.105969. Epub 2020 Apr 9.
8
Application of Artificial Intelligence in COVID-19 drug repurposing.人工智能在新冠病毒药物研发中的应用。
Diabetes Metab Syndr. 2020 Sep-Oct;14(5):1027-1031. doi: 10.1016/j.dsx.2020.06.068. Epub 2020 Jul 3.
9
Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base.羟氯喹在COVID-19危重症患者管理中的应用：循证依据的必要性。
Lancet Respir Med. 2020 Jun;8(6):539-541. doi: 10.1016/S2213-2600(20)30172-7. Epub 2020 Apr 15.
10
Dexamethasone nanomedicines for COVID-19.用于治疗新冠肺炎的地塞米松纳米药物。
Nat Nanotechnol. 2020 Aug;15(8):622-624. doi: 10.1038/s41565-020-0752-z.
引用本文的文献
1
Integrating Molecular Dynamics, Molecular Docking, and Machine Learning for Predicting SARS-CoV-2 Papain-like Protease Binders.整合分子动力学、分子对接和机器学习以预测严重急性呼吸综合征冠状病毒2（SARS-CoV-2）木瓜样蛋白酶结合物
Molecules. 2025 Jul 16;30(14):2985. doi: 10.3390/molecules30142985.
2
Structural and Functional Characterization of Medicinal Plants as Selective Antibodies towards Therapy of COVID-19 Symptoms.药用植物作为治疗新冠症状的选择性抗体的结构与功能表征
Antibodies (Basel). 2024 May 7;13(2):38. doi: 10.3390/antib13020038.
3
Memory augmented recurrent neural networks for de-novo drug design.基于记忆增强的循环神经网络用于从头药物设计。
PLoS One. 2022 Jun 23;17(6):e0269461. doi: 10.1371/journal.pone.0269461. eCollection 2022.
4
5G, Big Data, and AI for Smart City and Prevention of Virus Infection.5G、大数据和人工智能助力智慧城市与病毒感染防控
Adv Exp Med Biol. 2022;1368:189-214. doi: 10.1007/978-981-16-8969-7_9.
5
COVID-19: A systematic review and update on prevention, diagnosis, and treatment.新型冠状病毒肺炎：预防、诊断及治疗的系统评价与更新
MedComm (2020). 2022 Feb 17;3(1):e115. doi: 10.1002/mco2.115. eCollection 2022 Mar.
6
Impact of novel microbial secondary metabolites on the pharma industry.新型微生物次生代谢产物对制药行业的影响。
Appl Microbiol Biotechnol. 2022 Mar;106(5-6):1855-1878. doi: 10.1007/s00253-022-11821-5. Epub 2022 Feb 21.
7
Repurposable drugs for SARS-CoV-2 and influenza sepsis with scRNA-seq data targeting post-transcription modifications.利用针对转录后修饰的单细胞RNA测序数据筛选可用于治疗SARS-CoV-2和流感败血症的可重新利用药物。
Precis Clin Med. 2021 Aug 28;4(4):215-230. doi: 10.1093/pcmedi/pbab022. eCollection 2021 Dec.
8
Functionalized Dendrimer Platforms as a New Forefront Arsenal Targeting SARS-CoV-2: An Opportunity.功能化树枝状大分子平台作为靶向新型冠状病毒的前沿新武器库：一次机遇。
Pharmaceutics. 2021 Sep 18;13(9):1513. doi: 10.3390/pharmaceutics13091513.
9
Artificial Intelligence in Surveillance, Diagnosis, Drug Discovery and Vaccine Development against COVID-19.人工智能在新冠疫情的监测、诊断、药物研发及疫苗开发中的应用
Pathogens. 2021 Aug 18;10(8):1048. doi: 10.3390/pathogens10081048.
10
Network-based repurposing identifies anti-alarmins as drug candidates to control severe lung inflammation in COVID-19.基于网络的再利用将抗警报素鉴定为控制 COVID-19 严重肺部炎症的药物候选物。
PLoS One. 2021 Jul 22;16(7):e0254374. doi: 10.1371/journal.pone.0254374. eCollection 2021.
本文引用的文献
1
Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using Structure-Based Virtual Screening Approach.基于结构的虚拟筛选方法通过药物再利用鉴定 SARS-CoV-2 细胞进入抑制剂。
Front Immunol. 2020 Jul 10;11:1664. doi: 10.3389/fimmu.2020.01664. eCollection 2020.
2
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.基于网络的2019新型冠状病毒（2019-nCoV/SARS-CoV-2）药物重新利用研究
Cell Discov. 2020 Mar 16;6:14. doi: 10.1038/s41421-020-0153-3. eCollection 2020.
3
Real estimates of mortality following COVID-19 infection.新冠病毒感染后死亡率的实际估计值。
Lancet Infect Dis. 2020 Jul;20(7):773. doi: 10.1016/S1473-3099(20)30195-X. Epub 2020 Mar 12.
4
Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds.通过对 13 亿种化合物进行深度对接，快速鉴定 SARS-CoV-2 主要蛋白酶的潜在抑制剂。
Mol Inform. 2020 Aug;39(8):e2000028. doi: 10.1002/minf.202000028. Epub 2020 Mar 23.
5
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.与急性呼吸窘迫综合征相关的新型冠状病毒肺炎的病理表现
Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18.
6
A pneumonia outbreak associated with a new coronavirus of probable bat origin.一种新型冠状病毒引发的肺炎疫情，该病毒可能来源于蝙蝠。
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.
7
Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets.用于癌症治疗的计算机辅助药物重新利用：挑战抗癌靶点的方法与机遇
Semin Cancer Biol. 2021 Jan;68:59-74. doi: 10.1016/j.semcancer.2019.09.023. Epub 2019 Sep 25.
8
Drug repurposing: progress, challenges and recommendations.药物重定位：进展、挑战和建议。
Nat Rev Drug Discov. 2019 Jan;18(1):41-58. doi: 10.1038/nrd.2018.168. Epub 2018 Oct 12.
Zotero 插件